ESMO: Tubulis’ next-gen ADC posts 59% response rate, justifying investor interest – Fierce Biotech

Written by

admin

in

  1. ESMO: Tubulis’ next-gen ADC posts 59% response rate, justifying investor interest  Fierce Biotech
  2. German biotech firm Tubulis raises $358 million to develop targeted cancer treatments  MSN
  3. Tubulis lands record 308 million euro funding to advance ADC pipeline  The Pharma Letter
  4. Wellington Management Joins $361M Series C for Cancer Drug Developer Tubulis  citybiz
  5. Research transfer: LMU spin-off Tubulis secures financing for cancer research  LMU München

Continue Reading

More posts